Shares of
Bionano Genomics (NASDAQ:BNGO) hit a record high on Friday. By the close of trading, the genome analysis company s stock price was up 17%.
So what
On Thursday, Bionano Genomics released a study showing that its Saphyr optical genome mapping (OGM) system could be used to analyze a wide variety of solid tumors in cancer research. In every sample tested, Saphyr was able to identify structural variants (SVs) affecting key cancer genes. OGM will yield unprecedented insights into solid tumor diagnosis and treatment, study lead Dr. James Broach said in a press release.
Image source: Getty Images. Dr. Broach s work now demonstrates that Saphyr is uniquely capable of identifying clinically important SVs in solid tumor samples as well and that it does so with a simple, automated analysis workflow, Bionano CEO Erik Holmlin said.
Gene mutations linked to worse leukemia outcomes in Hispanic and Latino children
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino children, according to Penn State College of Medicine researchers. They said a novel therapeutic drug combination as well as testing for these mutations may help address the disparity.
Hispanic and Latino children are between 1.2 and 1.75 times more likely to develop B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, than non-Hispanic and Latino children. They also have a 40% higher death rate than their counterparts after correcting for socioeconomic factors. Dr. Sinisa Dovat, a researcher and pediatric oncologist at Penn State Children’s Hospital and Penn State Cancer Institute, partnered with Dr. Gordana Raca of Children’s Hospital Los Angeles and Kimberly J. Payne of Loma Linda University to understand the biology behin
E-Mail
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino children, according to Penn State College of Medicine researchers. They said a novel therapeutic drug combination - as well as testing for these mutations - may help address the disparity.
Hispanic and Latino children are between 1.2 and 1.75 times more likely to develop B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, than non-Hispanic and Latino children. They also have a 40% higher death rate than their counterparts after correcting for socioeconomic factors. Dr. Sinisa Dovat, a researcher and pediatric oncologist at Penn State Children s Hospital and Penn State Cancer Institute, partnered with Dr. Gordana Raca of Children s Hospital Los Angeles and Kimberly J. Payne of Loma Linda University to understand the biology behind this health disparity after prior research suggested that there may be an increase